Ann-Tove Kongsnes
Investment Director @ Investinor
Trondheim, Norway
Ann-Tove Kongsnes is a Series A investor at Investinor in Trondheim focused on Health Care and Biotechnology. Ann-Tove Kongsnes holds an MSc in Economics and Business Administration from Bodø College (HiB) and the Advanced Program in Corporate Finance at the Norwegian School of Economics (NHH). She was previously an investment manager at ProVenture Managment AS, Business Development Manager at Leiv Eiriksson Nyskaping AS, Director of Marketing &Operations at NSEC Inc and Marketing Manager at the Norwegian Seafood Export Council. Mrs Kongsnes is a board member of Investinor’s portfolio companies Ayanda AS, Nordic Seafarms AS, poLight AS, Pharmalink AB, Soundrop AS and Gassecure AS. She is also deputy board member at BerGenBio AS and head of International Affairs at Investinor.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries Ann-Tove Kongsnes invests in
Stages Ann-Tove Kongsnes invests in
Countries Ann-Tove Kongsnes invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (33%)
- Biotechnology 3 (33%)
- Manufacturing 2 (22%)
- Medical 1 (11%)
- Hardware 1 (11%)
Stage
- Series A 2 (22%)
- Funding Round 2 (22%)
- Venture - Series Unknown 2 (22%)
- Series B 1 (11%)
- Series C 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CardioMech is a developer of therapeutic devices for structural heart disease that provides a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve. The company's devices are used for the placement of artificial chords, enabling surgeons to get access to new therapeutic options for heartdiseases. The technology is being developed to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or flail.CardioMech was founded in 2015 and is headquartered in Trondheim, Norway. | $18.5M / Series A / Aug 05, 2020 | ||
| Phoenix Solutions AS is a Norwegian biotech company developing a technology platform for targeted drug delivery. | Venture - Series Unknown / Mar 01, 2017 | ||
| poLight is developing micro optics components. The technology is based on proprietary and patented methods for creating active optical components based on deformable polymers. poLight's main project is to develop the world's smallest and most cost-efficient auto focus lens for micro cameras. The poLight technology is characterized bywafer scale manufacturability, compact size, low cost and high optical quality. poLight is based in Horten, outside Oslo, Norway. | $19.5M / Aug 15, 2016 | ||
| BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $25.3M / Series D / Mar 18, 2016 | ||
| poLight is developing micro optics components. The technology is based on proprietary and patented methods for creating active optical components based on deformable polymers. poLight's main project is to develop the world's smallest and most cost-efficient auto focus lens for micro cameras. The poLight technology is characterized bywafer scale manufacturability, compact size, low cost and high optical quality. poLight is based in Horten, outside Oslo, Norway. | $19M / Venture - Series Unknown / Feb 06, 2015 | ||
| BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $12.5M / Series C / Feb 05, 2014 | ||
| BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $6M / Series B / May 01, 2013 | ||
| BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $8.8M / Series A / Jan 09, 2012 | ||
| ConCordix is a product of Vitux AS. Vitux is a third-party manufacturer providing private label products for the nutraceutical and dietary supplement industry. | Jul 08, 2010 |
Co-Investors
About Investinor
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Investinor Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bent Grøver
Principal
|
|||
Otto Frøseth
Investment Director
|
|||
|
Ann-Tove Kongsnes
Investment Director
|
|||
Birgitte Gangmark Villmo
Investment Manager
|
|||
Egil Garberg
Investment Associate
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ann-Tove Kongsnes invest in?
Ann-Tove Kongsnes invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series A and Funding Round stage. Most of the 9 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ann-Tove Kongsnes?
Public channels for Ann-Tove Kongsnes include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ann-Tove Kongsnes last invest?
The most recent investment recorded for Ann-Tove Kongsnes closed in Aug 2020. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
